



PRESS RELEASE

AbbVie appoints Sarah Bridge as Market Access Director, ANZ

SYDNEY, AUSTRALIA, 24 February 2025 – AbbVie (NYSE: ABBV) today announced the appointment of Sarah Bridge as the new Market Access Director for Australia and New Zealand.

Sarah commenced in the role at the end of January and is based in Sydney. Sarah is reporting to Nathalie McNeil, VP and General Manager of AbbVie ANZ.

With over 20 years of industry experience, Sarah joins AbbVie from Bayer Australia & New Zealand, where she held pivotal roles including Head of Market Access & Health Policy and Commercial Lead for Pipeline Assets. Prior to her tenure at Bayer, she was responsible for managing the local Market Access function and led regional initiatives supporting market access capability development at Eli Lilly.

Welcoming Sarah to the role, Nathalie McNeil, VP and General Manager of AbbVie ANZ said: "Sarah's appointment reinforces our commitment to advancing access to innovative therapies and healthcare solutions for patients across Australia and New Zealand. Sarah's extensive expertise and leadership will be instrumental as we continue to navigate the evolving healthcare landscape. Sarah's arrival marks a pivotal moment for AbbVie as we re-envision access and embrace the future with enthusiasm."

"We also congratulate Kathy Cargill on her retirement and thank her for her significant contribution toward ensuring access to innovative medicines for countless Australian patients with unmet needs," she said.

Commenting on her new role, Sarah said, "Joining AbbVie is a wonderful opportunity to work with an exceptional team dedicated to improving people's lives. I'm also excited about the future and fueling opportunities where our employees' ambition meets our dedication to building talent to strengthen and enrich both local and global talent pipelines."

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.au. Follow @abbvie on [Twitter](#), [Facebook](#), [Instagram](#), [YouTube](#) and [LinkedIn](#).

Further details: media_anz@abbvie.com